Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult2. fázis

Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues

A legfontosabb adatok

Ki végzi
Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Fázis
2. fázis
Résztvevők
120 fő, tervezett
Kezdés
2026. okt. 30.
Várható befejezés
2029. márc. 14.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • YKYY013
  • YKYY013 Placebo
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • Body Mass Index (BMI) between 18.0 to 32.0 kg/m\^2 (inclusive) and body weight equal to or over 50 kg for male and 45 kg for female
  • Chronic HBV infection , with positive hepatitis B surface antigen (HBsAg) or HBV DNA for at least 6 months, and continuous stable treatment with a single nucleoside (acid) analogue (NA) for ≥ 6 months; 3)HBeAg-negative at screening; 4)100 IU/mL < HBsAg ≤ 5000 IU/mL at screening; 5)HBV DNA < 100 IU/mL at screening. 6) Medically approved contraception (e.g., intrauterine device, oral contraceptive, condom) during the trial and for 6 months after the last dose, Participants must not donate sperm or ova during the trial or for 6 months after the last dose
  • The participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening

Ki nem vehet részt

  • Severe allergic reactions, non-allergic drug reactions, multiple drug allergies, or known hypersensitivity to the investigational drug or its excipients
  • Major illness or major surgery (excluding minor outpatient procedures) within 3 months before screening, or planned grade 3-4 surgery during the trial
  • Interferon or immunosuppressant treatment within 12 months before screening, excluding short-term (2 weeks or less) use and topical or inhaled corticosteroids
  • Live vaccine within 1 month before screening
  • Small interfering RNA (siRNA) drug trial within 6 months, or other investigational drug within 3 months, before screening; or planned participation in another interventional trial
  • Chronic liver disease other than chronic HBV infection (e.g., severe fatty liver, alcoholic, autoimmune, or inherited metabolic liver disease)
  • Current or past hepatic decompensation (e.g., esophagogastric variceal bleeding, ascites, hepatic encephalopathy)
  • Liver cancer history, or imaging (ultrasound, MRI, CT) suggesting liver cancer, or alpha-fetoprotein (AFP) at least 50 ug/L
  • Cardiovascular events (e.g., stroke, transient ischemic attack, myocardial infarction, unstable angina, coronary bypass surgery, percutaneous coronary intervention, heart failure hospitalization) or clinically significant valvular heart disease. Other chronic diseases considered unsuitable by the investigator (e.g., respiratory, endocrine, immune, renal, hepatic, gastrointestinal, dermatologic, hematologic, neurologic)
  • Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage) or bleeding tendency (e.g., recurrent gingival bleeding); cured disease without active or clinically significant bleeding may be enrolled at investigator discretion
  • Severe infection within 1 month, or infection symptoms within 7 days, before screening
  • Malignancy within 5 years, except cured resected in situ carcinoma (e.g., non-melanoma skin cancer)
  • AIDS, hepatitis A, B, C, or D, or positive screening for HIV antibody, Treponema pallidum antibody, or hepatitis A, B, C, or D antibody; positive hepatitis C antibody requires HCV RNA testing, and positive HCV RNA excludes
  • Any potentially hepatotoxic drug (prescription, over-the-counter, or herbal) within 14 days (or 5 half-lives, if longer) before the first dose, if judged unsuitable by the investigator; stable therapy for hypertension or diabetes is allowed
  • Difficult venous access or venipuncture intolerance; history of syncope or hematophobia
  • Inability to communicate or cooperate due to neurologic or psychiatric disorder or language barrier
  • Fridericia-corrected QT interval (QTcF) at least 450 msec (male) or 470 msec (female); if the first ECG exceeds these limits, two more ECGs are done and the mean of three applies
  • Significant laboratory abnormalities at screening, including:; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at least 2 times the upper limit of normal (ULN); Total bilirubin at least 2 times ULN with direct bilirubin above ULN; Serum albumin below 35 g/L; Platelets below 100 x 10\^9/L; Prothrombin time (PT) prolonged by more than 3 seconds, international normalized ratio (INR) above 1.3, or clinically significant fibrinogen abnormality; Creatinine clearance (Cockcroft-Gault) 60 mL/min or less, or clinically significant proteinuria; Poorly controlled diabetes with glycated hemoglobin (HbA1c) above 7.0%
  • Liver stiffness measurement (LSM) above 9 kPa at screening, or Metavir F3 or higher on biopsy within 1 year before screening
  • Clinically significant abnormalities on physical examination, vital signs, 12-lead electrocardiogram (ECG), or chest CT at screening
  • Uncontrolled blood pressure at screening (systolic at least 160 mmHg or diastolic at least 100 mmHg despite treatment)
  • Severe intolerance to subcutaneous injection (mild local reactions are acceptable)
  • Pregnancy, lactation, or positive pregnancy test at screening or baseline
  • Any scientific, compliance, or safety reason for which the investigator considers participation unsuitable

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the efficacy of YKYY013 in patients with chronic hepatitis B virus (HBV) infection with negative hepatitis B e antigen (HBeAg) and treated with nucleoside (acid) analogs (NA).

A vizsgálat 2 csoportja

  • YKYY013Már használt kezelés, összehasonlításként

    Drug: YKYY013 Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

  • YKYY013 PlaceboPlacebo, összehasonlításként

    Drug: 0.9% Sodium Chloride Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-blind, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY013 in Patients With HBeAg-negative Chronic Hepatitis B Virus Infection Treated With Nucleos(t)Ide Analogs
Kérdések a feltételekről
Forrás: NCT07933627: ki vehet részt
A regiszteradat frissítve
2026. november 12.